Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Nothing

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 12, 2021 7:15pm

209 Views

Post# 32982400

RE:RE:RE:RE:RE:RE:RE:Nothing

Wednesday's quarterly conference call

After that, we have news expected on the new version of Trogarzo coming before too much longer, although it is hard to see that as very catalyzing.

At any point, the company, or the doctors involved in the TH-1902 trial as we have seen with Dr. Shah, might share information about the safety aspect of the trial.

At any time, we might hear that the company has finalized their conversations with the FDA and EMA on the NASH trial.

The catalysts we most need to see are ones involving pitching the very intriguing story and great value TH shares represent to a wider audience of potential investors.